ATProto Browser

Record data

{
  "uri": "at://did:plc:qr3hg56of3beoarucejnickq/app.bsky.feed.post/3lmiempmops2y",
  "cid": "bafyreibmlshlbfchko3332us2kn6cv3lvhoprbifkjrpa63f6ljpwhlqr4",
  "value": {
    "text": "This FDA office enabled all of the first time generic drug approvals in the U.S. Their work helped substantially lower drug costs and increase competition during President Trump’s first term, including spearheading approval of the first generic EpiPen in 2018. This office has now been eliminated",
    "$type": "app.bsky.feed.post",
    "embed": {
      "$type": "app.bsky.embed.external",
      "external": {
        "uri": "https://www.thefdalawblog.com/2025/04/the-great-rift-one-fda-divisions-destruction-and-what-it-could-mean-for-generic-drugs/",
        "thumb": {
          "$type": "blob",
          "ref": {
            "$link": "bafkreih2j7lralj6dah6fc7igqcvwcj2xnqzjtal42xpsrbwo7qcomi3tu"
          },
          "mimeType": "image/jpeg",
          "size": 2029
        },
        "title": "The Great RIF(T): One FDA Division’s Destruction and What it Could Mean for Generic Drugs",
        "description": "The FDA Reduction-in-Force (Termination)—or “RIF(T)”—announced last week has resulted in countless stories in the press and on personal LinkedIn accounts from those RIF’d.  As the dust begins to se…"
      }
    },
    "langs": [
      "en"
    ],
    "createdAt": "2025-04-10T20:44:02.017Z"
  }
}